Research Article
Clinical Characteristics and Outcomes of Patients Hospitalized with COVID-19 at Case Hospital, Uganda
Table 3
Treatment modalities administered to patients admitted at case hospital.
| | Medication (N = 160) | Received: frequency (%) | Modal dose (%) | Duration (median days, IQR) |
| | Azithromycin | 123 (76.9) | 500 mg | 3 (2–5) | | Dexamethasone | 120 (75) | 4 mg (41.2%) | 3 (2–4.5) | | Vitamin C | 114 (71.3) | 500 mg | 4 (2–5) | | Vitamin D | 114 (71.3) | 1000 IU | 4 (2–5) | | Enoxaparin | 113 (70.6) | 40 mg (50%) | 3 (2–5) | | Zinc | 106 (66.3) | 20 mg | 3 (2–5) | | Ulinastatin | 96 (60) | 100000 IU (60.2%) | 3 (2–5) | | Ivermectin | 18 (11.3) | 12 mg | 3.5 (2–5) | | Remdesivir | 13 (8.1) | 100 mg | 4 (2–4) | | Warfarin | 1 (0.6) | 2.5 mg | 2 (NA) |
|
|
